Repair Biotechnologies raised $11.42 million to advance REP-0003, an FDA-designated orphan drug mRNA therapy for the treatment of homozygous familial hypercholesterolemia, an ultra-rare genetic disorder causing severely elevated cholesterol and accelerated atherosclerosis.
